Meanwhile, Merck's ProQuad, MMR II and Varivax vaccines recorded combined sales of $316 million, up 9%. Vytorin sales declined 3% to $445 million during the quarter. Merck's hepatitis C treatment, Victrelis (boceprevir) posted sales of $126 million, up from $111 million, $87 million, and $31 million reported in the last three quarters. We were encouraged to see the sequential improvement in Victrelis sales. Victrelis was added to the VA formulary, which is the largest single provider of services to hepatitis C patients in the US. This represents a significant commercial opportunity for Victrelis. Merck has an agreement with Roche ( RHHBY ) for the global marketing of Victrelis as part of a triple combination therapy. Emerging markets accounted for 18% of pharmaceutical sales in the second quarter of 2012 with China continuing to put in a strong performance. Merck's animal health segment posted sales of $865 million, up 8%. Increased sales of swine and cattle products helped drive growth.